Schedule III compliance hurdles crystallize as DEA registration becomes the next bottleneck; Texas THCA flower gets reprieve through July; Connecticut retains THC caps; Israel moves to eliminate smokable medical flower

The DOJ's rescheduling order does not immediately bring state-licensed operators into compliance with federal law, according to congressional researchers. Medical cannabis businesses must register with the DEA to operate legally under Schedule III. Green Thumb Industries (GTI) has filed applications for DEA registration, becoming one of the first major MSOs to do so. (Cannabis Business Times, May 4, 2026)

Impact · State-licensed cannabis operators now face a new federal compliance layer. DEA registration requirements could create a bottleneck, as the agency has limited experience processing cannabis-specific registrations at scale. Early applicants may gain competitive advantage through first-mover federal legitimacy, while operators who delay face potential enforcement exposure.

Action · Engage federal regulatory counsel this week to assess your DEA registration readiness; begin compiling security, record-keeping, and inventory control documentation required for Schedule III registrations before the inevitable backlog develops.

A Texas judge ruled that hemp merchants can continue selling THCA flower and pre-rolls until at least July 27, 2026 — the next trial date in an ongoing lawsuit challenging the state's smokable hemp product ban. The lawsuit was filed by the Texas Hemp Business Council, Hemp Industry & Farmers of America, and multiple retailers, manufacturers, and farmers. (MJBiz Daily and Ganjapreneur, May 4, 2026)

Impact · Texas THCA flower operators get a roughly three-month window to continue sales, but this is a reprieve, not a resolution. The July 27 trial date becomes the hard decision point. Operators must plan for two scenarios: continued sales or abrupt market exit.

Action · If you sell THCA flower in Texas, use this window to diversify product lines toward non-smokable hemp formats while maintaining flower revenue; do not expand flower-specific capital expenditures given the uncertain July outcome.

Israel's Health Ministry has recommended ending the use of smoked medical cannabis, proposing a shift to extracts and precision inhalers for patient delivery. (MJBiz Daily, May 4, 2026)

Impact · Israel is a global bellwether for medical cannabis regulation. If implemented, this policy would reshape product demand toward manufactured dosage forms, benefiting extraction and device companies while pressuring flower-dependent cultivators. Other medical cannabis markets may follow Israel's lead.

Action · Evaluate your product portfolio's exposure to smokable flower in medical markets; begin conversations with extraction and inhaler device partners now if you lack non-combustible product lines.

Connecticut lawmakers are walking back a plan to eliminate the state's THC cap on cannabis flower and concentrates. The House had previously approved language to remove caps, but lawmakers are now retaining them. Additionally, a proposed increase in THC caps for infused beverages sold in package stores from 3 milligrams was also addressed. (Ganjapreneur, May 4, 2026)

Impact · Product developers and cultivators targeting Connecticut must continue formulating within existing THC limits, constraining high-potency product launches. This signals that even in legalized states, potency regulation remains politically sticky and prone to last-minute reversals.

Action · Do not plan high-potency product launches for Connecticut; instead focus on terpene profiles, minor cannabinoids, and branding differentiation within existing THC limits.